- Biopharma News
Samsung Biologics adds fourth plant due to growing demand11 Aug 2020
Plant 4 will add 256 KL capacity to its site, which is scheduled to commence manufacturing activities in the second half of 2022.
Samsung Biologics has announced plans to break ground for a fourth plant within this year. This is part of its long-term strategy to maximize its operational efficiency and scale up its development and manufacturing capabilities in response to growing biomanufacturing demands.
The company is also in negotiations with the authorities at IFEZ (Incheon Free Economic Zone) to purchase additional land for its second bio complex.
The total size of the two investments is expected to be in excess of 2 trillion Korean won — roughly equivalent to 2 billion US dollars — and more than the total amount invested in the company’s previous three plants combined throughout its 9-year history.
Adding 256 KL capacity to its site, Plant 4 is scheduled to commence manufacturing activities in the second half of 2022, and further advance the company’s standing as the world’s largest manufacturing facility at a single location — holding a 620 KL total capacity upon completion.
Samsung Biologics is taking an innovative approach in the design strategy of its new plant: by incorporating the unique advantages from Plant 1, 2, and 3, it will offer multi-scale manufacturing services to support the diversifying needs of new and existing clients.
Construction will begin on an existing site with the plant comprising 23.8 million m2 in total floor area — the equivalent to the combined floor area of its existing three plants.
To maximize operational efficiency, Plant 4 will introduce real-time production schedule simulation through automation and latest biomanufacturing technologies as well as optimization of utility supply based on data collected from its current plants.
Samsung Biologics is also investing heavily in offsetting its facilities’ environmental impact. Newly advanced technologies such as streamlined application, smart disposal of high-concentration wastewater, and improvement of nitric acid emissions will strengthen the environment of the workplace and community.
The land under negotiation for Samsung Biologics’ second bio complex is closely located to the company’s current complex, and is slightly larger at 330,000 m2. Once the terms are finalized, the company plans to create an Open Innovation center to foster biotech companies and build a global R&D facility in addition to securing space for future plants within the new complex.
Dr Tae Han Kim, CEO of Samsung Biologics, said: “With the production of Plant 4, our ‘Super Plant,’ Samsung Biologics is investing in a total line refinement and addition of new mid- and small-scale facilities to ensure production efficiency and provide top-notch services.”
Are you a supplier?
Here's what CPhI Online can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation